Speaker

Dirk van Asseldonk | CEO, LentiCure

Dirk is a serial entrepreneur in Life Sciences and MedTech. In 2004 he founded Dolphys Medical to bring an on/off switchable drug delivery implant to market. Later he turned the business into a patient ventilation and airway management company, continuing and expanding in a new start-up company Ventinova Medical, established in 2012. With a large patent portfolio and active innovation management as basis, he raised over 25M capital and grew the company to 25 people, with sales in many European countries and starting in the Middle East and the USA. In 2021 the company was profitable; he left in 2022 to pursue new challenges. In 2023 he established LentiCure BV: he now leads this social enterprise (100% affiliate of ErasmusMC) aiming to stop rare lysosomal storage diseases with lentiviral gene therapy.

LentiCure

Being a social enterprise, LentiCure BV is a 100% affiliate company of ErasmusMC and will remain fully publicly owned. We bring lentiviral gene therapy to patients with a rare genetic disease against socially acceptable costs, and by that solving current market failure in this area. Our first focus is on Pompe disease, secondly Hunter Syndrome and then therapies for more of the 86 rare lysosomal storage diseases are to follow. Patients are already expressing their hopes on the solution we are developing, as it holds the promise to finally fully stop progression of their devastating disease. We are currently financed by charity and grants, and reaching out to health authorities for further support.

Powered by:
Hyphen Projects

Let's connect:

Book a ticket

FAQ
Contact Us
Privacy Policy
Terms & Conditions
Chamber of Commerce: 32110979
VAT no: NL8184.34.491.B01

Keep me informed Download our event app

© Copyright 2023 by Hyphen Projects